drugset / Trial / NCT01177800

A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis

NCT01177800

Phase 3 Completed 129 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the superiority and efficacy of infliximab induction therapy in chinese participants with moderate to severe plaque-type psoriasis (scaly skin rash) compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial).

Timeline

Start
2009-02
Primary completion
2010-02
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications